Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
stocks
Weekly earnings wrap: BHP, CSL, NAB and more
Materials, banking, healthcare and retail heavyweights reveal diverging outlooks.
stocks
Chart of the Week: Our top dividend stock picks on the ASX
Highlighting key income opportunities on the ASX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,298.50 | 9.60 | -0.10% |
| CAC 40 | 8,453.09 | 48.82 | -0.57% |
| DAX 40 | 25,983.04 | 108.29 | -0.42% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,748.16 | 4.81 | 0.04% |
| HKSE | 25,698.49 | 203.42 | 0.80% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,216.79 | 890.37 | 1.36% |
| NZX 50 Index | 13,919.82 | 9.85 | -0.07% |
| S&P 500 | 7,641.16 | 66.82 | -0.87% |
| S&P/ASX 200 | 9,083.80 | 18.00 | -0.20% |
| SSE Composite Index | 3,903.72 | 9.30 | 0.24% |